Key result
Alternate-day dosing of moderate-intensity rosuvastatin showed no statistically significant difference in LDL reduction compared to daily dosing (SMD -0.02), though non-inferiority was not established.
Why the study?
The comparative efficacy of alternate-day versus daily moderate-intensity (10 mg) rosuvastatin in managing lipid profiles required evaluation.
Does alternate-day moderate-intensity rosuvastatin improve lipid profiles similarly to daily dosing in patients with dyslipidemia?
Meta-Analysis (n=316)
Does alternate-day moderate-intensity rosuvastatin improve lipid profiles similarly to daily dosing in patients with dyslipidemia?
Standardized Mean Difference: -0.02 (95% CI -0.41–0.37)
p-value: p=0.90
Alternate-day dosing of 10 mg rosuvastatin significantly improves lipid parameters from baseline with no statistically significant difference compared to daily dosing, though non-inferiority is not definitively established.
No takes yet. Share an insight, caveat, or question.
Noninferiority of alternate-day rosuvastatin not established; leaves open optimal dosing frequency in dyslipidemia.
Objective To evaluate the comparative efficacy of alternate-day versus daily moderate-intensity (10 mg) rosuvastatin in managing lipid profiles. Methods A systematic literature review was conducted across PubMed, Scopus, Google Scholar, and EBSCOhost as of March 27, 2026. Six studies (four RCTs and two non-randomized) involving participants with dyslipidemia, hyperlipidemia, or T2DM-associated dyslipidemia were analyzed. All participants received moderate-intensity rosuvastatin. Pooled mean differences (MD) and standardized mean differences (SMD) were estimated using random-effects models. Results Alternate-day dosing yielded significant within-group improvements from baseline in total cholesterol (TC) (MD = -52.32, 95% CI: -69.02 to -35.61, p < 0.00001), triglycerides (TAG) (MD = -45.49, 95% CI: -77.21 to -13.78, p = 0.005), and low-density lipoprotein (LDL) (MD = -48.97, 95% CI: -58.05 to -39.88, p < 0.00001). High-density lipoprotein (HDL) increased significantly (MD = 4.58, 95% CI: 2.29 to 6.87, p < 0.0001). In direct post-intervention comparisons, no statistically significant differences were detected between alternate-day and daily dosing for TC (SMD = 0.01, 95% CI: -0.39 to 0.42, p = 0.94), TAG (SMD = 0.03, 95% CI: -0.19 to 0.25, p = 0.78), HDL (SMD = -0.03, 95% CI: -0.25 to 0.19, p = 0.80), or LDL (SMD = -0.02, 95% CI: -0.41 to 0.37, p = 0.90). Conclusion Alternate-day dosing of moderate-intensity rosuvastatin was associated with significant within-group improvements in lipid parameters. However, the absence of statistically significant between-group differences should not be interpreted as evidence of equivalence or non-inferiority, particularly because the confidence intervals remain compatible with potentially clinically meaningful differences. Alternate-day dosing may be considered an exploratory strategy in selected patients, but stronger evidence from adequately powered non-inferiority trials is needed.
Tiongco et al. (2026) conducted a meta-analysis in Dyslipidemia (n=316). Alternate-day rosuvastatin vs. Daily rosuvastatin was evaluated on Low-density lipoprotein (LDL) reduction (SMD -0.02, 95% CI -0.41 to 0.37, p=0.90). Alternate-day dosing of moderate-intensity rosuvastatin showed no statistically significant difference in LDL reduction compared to daily dosing (SMD -0.02), though non-inferiority was not established.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: